TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* (a) Estimated age ≥ 15 years. Older minimum age is required in some locations. FOR United Kingdom: Estimated or actual age ≥ 16 years FOR Australia: Estimated or actual age ≥ 18 years AND (b) Estimated or actual weight ≥ 50 kg (110 lbs).~* Traumatic injury with confirmed or suspected acute major bleeding and/or Revised Assessment of Bleeding and Transfusion (RABT) score ≥ 2~* Activation of massive transfusion protocol~Exclusion Criteria:~* Healthcare professional cardiopulmonary resuscitation including chest compressions for ≥ 5 consecutive minutes at any time before randomization~* Isolated penetrating or blunt cranial injury, or exposed brain matter~* Isolated burns estimated to be \> 20% total body surface area or suspected inhalational injury~* Known anticoagulation treatment or a history of a TEE, within the past 3 months.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BE1116 (Type: EXPERIMENTAL): Administration by IV infusion
- Placebo (Type: PLACEBO_COMPARATOR): Administration by IV infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with moderate to severe ulcerative colitis (UC) who have not responded despite a full and adequate course of therapy with a corticosteroid and an immunosuppressant (AZA/6-MP); or who are intolerant to or have medical contraindications for such therapies and are hence prescribed adalimumab for the treatment of moderate to severely active UC~* Patients who are able to complete patients questionnaires (e.g., WPAI:UC and sIBDQ questionnaire)~* Patients must fulfill national and international guidelines for the use of biologic therapies in UC (Chest X-ray and Interferon-Gamma-Release Assay (IGRA) or tuberculin purified protein derivative (PPD)-skin test negative for tuberculosis).~* Patients who have been prescribed adalimumab in line with the European SmPC (Summary of Product Characteristics)~Exclusion Criteria:~* Previous therapy with TNF-alpha (Tumor necrosis factor alpha) blocker~* No signed written authorization to use data~* Contraindication to adalimumab therapy according to the SmPC~* Patients with a history of subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Koch pouch, or ileostomy for UC or planned bowel surgery.~* Patients received intravenous (IV) corticosteroids within 14 days of Screening or during the Screening period.~* Pregnant patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Moderate to Severe Ulcerative Colitis (Type: None): Patients with moderate to severe ulcerative colitis (UC) who have not responded despite a full and adequate course of therapy with a corticosteroid and an immunosuppressant (azathioprine \[AZA\]/ 6-mercaptopurine \[6-MP\]); or who are intolerant to or have medical contraindications for such therapies and are hence prescribed adalimumab for the treatment of moderate to severely active UC.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have a diagnosis of CLL/SLL and be previously treated~2. Patients must have had Fluorescence in situ Hybridization (FISH) evaluation of leukemia cells within 3 months without intervening treatment demonstrating deletion 11q22-23~3. Patients must have an indication for treatment by 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Criteria~4. Age \>/= 18 years~5. Eastern Cooperative Oncology Group (ECOG)/Zubrod performance status \</= 2~6. Adequate renal and hepatic function as indicated by all the following: serum creatinine \</= 2 mg/dL AND; alanine aminotransferase (ALT) \</= 2.5 times upper limit of normal; AND total bilirubin \</= 2.5 times upper limit of normal~7. Patients must have an Absolute neutrophil count (ANC) \>/= 500/uL, Hemoglobin (HGB) \>/= 8 gm/dL, Platelets (PLT) count \>/= 20K/uL, unless attributed to marrow infiltration with CLL~8. Patients must give written informed consent~9. Patients of childbearing potential (females who have not been postmenopausal for at least 12 consecutive months or who have not undergone previous surgical sterilization or males who have not been surgically sterilized) must be willing to practice birth control during the study~Exclusion Criteria:~1. Pregnant or breast-feeding females~2. Significant co-morbidity indicated by major organ system dysfunction~3. Active infection, uncontrolled with intravenous antibiotics~4. Uncontrolled autoimmune hemolytic anemia (AIHA) or immune thrombocytopenia purpura (ITP)~5. Treatment including chemotherapy, chemoimmunotherapy, monoclonal antibody therapy, radiotherapy, high-dose corticosteroid therapy (prednisone \>/= 60 mg daily, or equivalent), or immunotherapy within 3 weeks prior to enrollment or concurrent with this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cyclophosphamide, Rituximab + Sapacitabine (Type: EXPERIMENTAL): After Sapacitabine 350 mg orally Days 1-3, Cyclophosphamide 250 mg/m2 IV 2 hours, followed by Rituximab 375 mg/m2 IV Day 3, Course 1, and 500 mg/m2 Day 1, subsequent courses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: MOUVSCO: Kinematic Analysis of the Trunk in Patients With Moderate Scoliosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Scoliosis Group - Inclusion Criteria:~* female children patients from 9 to 16 years old,~* patients with idiopathic scoliosis lumbar left and / or right thoracic,~* patients with moderate scoliosis: Cobb angle measured on a radiograph between 10 ° and 25°,~* both parents of patients must be affiliated to social security or similarly regime.~Healthy Volunteers Group - Inclusion Criteria:~* female children from 9 to 16 years old, matched in age and size with scoliosis patients,~* children with no neuromuscular disease that may have an influence on the required tasks,~* both parents of children must be affiliated to social security or similarly regime,~Exclusion Criteria:~* refusal to consent: from child's in age to consent or from both parents

- Gender: FEMALE
- Minimum Age: 9 Years
- Maximum Age: 16 Years
- Healthy Volunteers: t

Study Arms:
- Scoliosis Group (Type: EXPERIMENTAL): None
- Healthy Volunteers Group (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of the CLP® Hip - Retrospective

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients must be 18 years of age or older.~2. Noninflammatory degenerative joint disease including~   * Osteoarthritis of the natural femoral head~  * Avascular necrosis of the natural femoral head~  * Rheumatoid arthritis~3. Correction of functional deformities~4. Femoral fracture~5. Patients must be able and willing to complete all study-related visits.~Exclusion Criteria:~1. Anyone who is under 18 years of age~2. Infection or sepsis~3. Insufficient bone quality which may affect the stability of the implant~4. Muscular, neurological or vascular deficiencies, which compromise the affected extremity~5. Skeletally immature patients and cases where there is a loss of abductor musculature, poor bone stock, poor skin coverage around hip joint which would make the procedure unjustifiable~6. Osteomyelitis~7. Rapid joint destruction or bone absorption apparent on roentgenogram~8. Pathological conditions of the acetabulum which would prevent achieving proper range of motion, appropriate head stability, and/or a well-seated and supported smooth articulation of the head within the acetabulum~9. Alcoholism or other addictions~10. Materials sensitivity~11. Loss of ligamentous structures~12. High levels of physical activity (e.g., competitive sports, heavy physical labor)~13. Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CLP Hip (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evolution of Neuropathies Associated With Necrotizing Vasculitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Adult patient with an initial diagnosis or a relapse of :~- Systemic Vasculitic Neuropathy (SVN): Primary Necrotizing Vasculitis answering the Chapel Hill Consensus Conference criteria associated with a symptomatic Vasculitic Peripheral Neuropathy~Or~- Non Systemic Vasculitic Neuropathy (NSVN): pure symptomatic peripheral neurological impairment without systemic visceral impairment~Exclusion Criteria:~* Symptomatic peripheral neurological impairment not attributable exclusively to primary necrotizing vasculitis~* Diabetes~* Chronic ethylism~* AL (immunoglobulin light chain) amyloidosis or TTR (transthyretin)~* Genetic neuropathies~* Toxic neuropathies~* Sequelae of sciatica~* Opposition to participation in the study~* Lack of social security~* Under guardianship or curatorship

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- Necrotizing Vasculitis (Type: None): Patient with an initial diagnosis or a relapse of :~- Systemic Vasculitic Neuropathy (SVN): Primary Necrotizing Vasculitis answering the Chapel Hill Consensus Conference criteria associated with a symptomatic Vasculitic Peripheral Neuropathy~Or~- Non Systemic Vasculitic Neuropathy (NSVN): pure symptomatic peripheral neurological impairment without systemic visceral impairment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Oxaliplatin, Capecitabine, and Bevacizumab to Treat Older Patients With Colorectal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 65 years and above;~* Histologically or cytologically documented adenocarcinoma of the colon or rectum;~* Metastatic disease;~* Measurable disease or assessable but nonmeasurable disease allowed;~* ECOG 0-1~* No prior oxaliplatin or bevacizumab.~* No prior chemotherapy for metastatic disease. Prior adjuvant chemotherapy allowed;~* No prior fluoropyrimidine therapy (unless give in an adjuvant setting and completed at least 4 months earlier);~* No bleeding diathesis or coagulopathy~* Adequate renal and hepatic functions as per protocol;~* Signed informed consent~Exclusion Criteria:~* Clinically significant cardiovascular or peripheral vascular disease;~* Concurrent chronic aspirin, nonsteroidal anti-inflammatory drugs, warfarin, or therapeutic heparin;~* Serious non-healing wound, ulcer, or bone fracture;

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Association Between Peri-Operative Hyperglycemia and Major Morbidity and Mortality

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled for non emergent surgery under either general or regional anesthesia deemed to have moderate to high physiologic stress~* Male and female subjects over the age of 18 with or without a diagnosis of diabetes mellitus~* Patients must be able to provide informed consent~Exclusion Criteria:~* Cognitively impaired~* Non-English or Spanish speaking with no relative present who is fluent in reading and comprehending English or Spanish.~* Female patients of child bearing age who have a positive pregnancy test on admission.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- intensive glycemic control (Type: EXPERIMENTAL): In the intensive treatment group, continuous insulin infusion (50 IU of Novolin R \[Novo Nordisk\]) in 50ml of 0.9% saline via infusion pump will be started when the blood glucose level exceeds 110 mg / dL on two consecutive samples and will be adjusted to maintain the blood glucose level between 80 and 110 mg / dL. If the glucose level falls below 80 mg / dL, the insulin infusion will be tapered and discontinued.
- conventional glycemic control (Type: ACTIVE_COMPARATOR): In this group if the subject's blood glucose level should exceed 200 mg/dL the subject will be treated with a continuous insulin infusion to maintain blood glucose levels between 180-200mg/dL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Transthoracic Echocardiographic Evaluation of the Cardiac Function During Transurethral Resection of Prostate in Elderly Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Above 65years of age~2. American Society of Anesthesiologists (ASA) Physical Status I, II, III.~3. undergoing transurethral resection of the prostate(TURP)~Exclusion Criteria:~1. severe coagulopathy or bleeding disorder(platelet count\<75000, PT INR \>1.2)~2. short stature (under 150 cm)~3. underwent coronary artery bypass graft~4. contraindications of regional anesthesia 

- Gender: MALE
- Minimum Age: 65 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: None): BPH patients with normal diastolic function
- Diastolic dysfunction (Type: None): BPH patients with preoperative diastolic dysfunction

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients followed for amyloidosis with proved cardiac injury or strongly suspected:~  * cardiac echography with typical signs of amyloid injury,~ * anatomical result confirming presence of amyloid deposits at cardiac or peripheral level~* Signature of Informed Consent Form,~* Affiliation to a social security system~Exclusion Criteria:~* Patient who suffers from another pathology which could lead cardiac injury (coronary disease, valvular disease, other pathology of deposit),~* Pregnancy and lactating women,~* Absence of effective contraception,~* Irradiating examination performed within the last 12 months or scheduled within the next 12 months,~* Unable patient physically, mentally or legally to provide informed consent,~* Patient under a system of legal protection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PET with 18 F-Flutemetamol (Type: EXPERIMENTAL): PET with 18 F-Flutemetamol (Vizamyl®) = product under Alzheimer's disease indication

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Determinants of Oral Anticoagulants' Activity

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient receiving direct oral anticoagulant~* Complete blood count and measure of hemostasis planned~* Patient able to give consent~* Patient with health insurance~Exclusion Criteria:~* Patient not able to consent~* Patient under 18 years old~* Patient refusal~* Patient without health insurance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anti-IIa users (Type: None): Determination of predictors of anticoagulant activity in a prospective cohort of patients using oral anti IIa anticoagulant including analysis of PK-PD genetic polymorphisms
- Anti-Xa users (Type: None): Determination of predictors of anticoagulant activity in a prospective cohort of patients using oral anti Xa anticoagulant including analysis of PK-PD genetic polymorphisms

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Identification of Volatile Organic Compounds in Exhaled Air During Exacerbation of Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria of COPD group:~* COPD stages 2 and 3 of GOLD score (30 ≤ forced expiratory volume at one second (FEV1) \< 80% of predicted value),~* exacerbation confirmed clinically (increased dyspnea, cough or expectorations \> 48 hours)~Inclusion Criteria of non COPD group:~* No smoker (\<100 cigarettes/year)~Exclusion Criteria of COPD group:~* Diagnosis of COPD not confirmed.~* Instable clinical status with respiratory failure and indication of mechanical ventilation.~* Bronchodilator treatment changed~* Antibiotic treatment started in the 10 last days before admission~Exclusion Criteria of non COPD group:~* Chronic inflammatory disease~* Any respiratory disease~* Oral corticosteroid treatment during the last month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- COPD Patients (Type: None): Patients with COPD, within 48h after hospital admission for exacerbation.
- non-COPD patients (Type: None): Healthy person of the entourage of COPD patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: 3D Geplante Osteosynthesen Mit Patientenspezifischen Zielvorrichtungen

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* fracture of clavicle, upper extremity, lower extremity or pelvis,tibia, fibula,Femur, with indication for fracture Fixation~* clinical indication for a computed tomography of the fractured bone~* \>18 years of Age~* Patient is able to give informed consent~Exclusion Criteria:~* pregnancy or nursing women~* non-compliance of the patient to follow the clinical study protocol, drug abuse or alcohol abuse~* participation in a different clinical Trial within the last 30 days before inclusion or during the study~* allergy to Polyamid PA 2200~* no available technique for fracture Fixation which could be performed, in case of applying the medical device is not possible.~* Applying the medical device is not possible, because of technical or anatomical reasons.~* other clinical significant accompanying symptoms (tumor, infection)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- patient specific guides (Type: EXPERIMENTAL): fracture fixation with 3D planning and use of patient-specific instruments
- standard procedure (Type: ACTIVE_COMPARATOR): standard procedure of fracture Fixation without 3D planning and without use of patient-specific instruments

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues